Is HLI a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Restructuring ballast, with revenue (fy2026, ended mar 2026) at ~$2.62B. The bear case rests on advisory revenue is inherently lumpy and tied to deal completions, so a prolonged M&A slowdown or credit freeze can pressure results even with the restructuring hedge. Analysts covering it are spread from $155.00 to $200.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Advisory revenue is inherently lumpy and tied to deal completions, so a prolonged M&A slowdown or credit freeze can pressure results even with the restructuring hedge. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $155.00, +10.2% from the $140.60 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Restructuring ballast. Houlihan Lokey runs one of the largest restructuring advisory practices in the world, consistently ranked in the top tier alongside PJT Partners and Evercore. The most optimistic analyst target on HLI is $200.00, +42.2% from the $140.60 price. That figure is only reachable if this thesis works close to its best case.

Advisory revenue is inherently lumpy and tied to deal completions, so a prolonged M&A slowdown or credit freeze can pressure results even with the restructuring hedge. The business depends heavily on retaining senior bankers, and competition for talent is intense against boutiques and bulge brackets alike. Fees can swing quarter to quarter based on the timing of transaction closings, making near-term earnings hard to forecast. The stock has traded at a premium multiple, which leaves less room for error if growth disappoints. Regulatory scrutiny of large restructurings and M&A, plus macro shocks to capital markets, are additional external factors outside the firm's control. The most pessimistic published target is $155.00, +10.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Houlihan Lokey, Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Restructuring ballast) stalling in the reported numbers rather than in the narrative, the risk above (advisory revenue is inherently lumpy and tied to deal completions, so a prolonged M&A slowdown or credit freeze can pressure results even with the restructuring hedge) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It is an independent global investment bank that provides advisory services: mergers and acquisitions advice, capital raising, financial restructuring for distressed companies and creditors, and valuation and financial opinions. It earns fees for advice rather than trading or lending.

Three: Corporate Finance (M&A and capital solutions, the largest), Financial Restructuring (bankruptcy and workout advisory), and Financial and Valuation Advisory (fairness opinions, portfolio valuation, and consulting). Corporate Finance is roughly two-thirds of revenue.

For the fiscal year ended March 31, 2026, revenue was roughly $2.62 billion, up about 10 percent from the prior year, with net income near $426 million and diluted EPS around $6.22 (adjusted EPS about $7.56).